Kai Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Kai Chen has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Akira Miyamoto
Department of Rehabilitation, West Kyushu University, Fukuoka, Japan
1 shared publication - Chi Zhang
Rehabilitation Medicine Department, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan Province, China
1 shared publication - Dechao Feng
Urology & Nephrology Center, Department of Urology, Zhejiang Provincial People’s Hospital (Affiliated People’s Hospital), Hangzhou Medical College, Hangzhou, China
1 shared publication - Dengxiong Li
Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China
1 shared publication - Jie Wang
Department of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan, China
1 shared publication - Koo Han Yoo
Department of Urology Kyung Hee University Seoul South Korea
1 shared publication
Latest Publications
- Open Access
- 12 March 2024
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 150 (3) , 1-16
A pan-cancer analysis of the oncogenic and immunological roles of transglutaminase 1 (TGM1) in human cancer
Background: There is currently a limited number of studies on transglutaminase type 1 (TGM1) in tumors. The objective of this study is to perform a comprehensive analysis across various types of cancer to determine the prognostic significance of TGM1 in tumors and investigate its role in the immune environment. Method: Pan-cancer and mutational data were retrieved from the TCGA database and analyzed using R (version 3.6.4) and its associated software package. The expression difference and prognosis of TGM1 were examined, along with its correlation with tumor heterogeneity, stemness, mutation landscape, and RNA modification. Additionally, the relationship between TGM1 expression and tumor immunity was investigated using the TIMER method. Results: TGM1 is expressed differently in various tumors and normal samples and is associated with the overall survival and progression-free time of KIRC, ACC, SKCM, LIHC, and STES. In LICH, we found a negative correlation between TGM1 expression and 6 indicators of tumor stemness. The mutation frequencies of BLCA, LIHC, and KIRC were 1.7%, 0.3%, and 0.3% respectively. In BLCA and BRCA, there was a significant correlation between TGM1 expression and the infiltration of CD4 + T cells, CD8 + T cells, neutrophils, and dendritic cells. Conclusion: TGM1 has the potential to serve as both a prognostic marker and a drug target.
- 12 March 2024
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 150 (3) , 1-16
Open AccessA pan-cancer analysis of the oncogenic and immunological roles of transglutaminase 1 (TGM1) in human cancer
Background: There is currently a limited number of studies on transglutaminase type 1 (TGM1) in tumors. The objective of this study is to perform a comprehensive analysis across various types of cancer to determine the prognostic significance of TGM1 in tumors and investigate its role in the immune environment. Method: Pan-cancer and mutational data were retrieved from the TCGA database and analyzed using R (version 3.6.4) and its associated software package. The expression difference and prognosis of TGM1 were examined, along with its correlation with tumor heterogeneity, stemness, mutation landscape, and RNA modification. Additionally, the relationship between TGM1 expression and tumor immunity was investigated using the TIMER method. Results: TGM1 is expressed differently in various tumors and normal samples and is associated with the overall survival and progression-free time of KIRC, ACC, SKCM, LIHC, and STES. In LICH, we found a negative correlation between TGM1 expression and 6 indicators of tumor stemness. The mutation frequencies of BLCA, LIHC, and KIRC were 1.7%, 0.3%, and 0.3% respectively. In BLCA and BRCA, there was a significant correlation between TGM1 expression and the infiltration of CD4 + T cells, CD8 + T cells, neutrophils, and dendritic cells. Conclusion: TGM1 has the potential to serve as both a prognostic marker and a drug target.